Aspirin resistance in cardiovascular disease: A review

European Journal of Vascular and Endovascular Surgery

Volumn 27, Issue 5, 2004, Pages 456-465

  Wong, S ^a   Appleberg, M ^a   Ward, C M ^a   Lewis, D R ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Aspirin resistance; Platelet; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HEART INFARCTION; HUMAN; MEDICAL RESEARCH; MEDLINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; STROKE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT FAILURE;

EID: 1942467385     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2003.12.025     Document Type: Review

References (60)

1. Alexander JH et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999; 83: 1147-1151.
2. Gum PA et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
3. Steering Committee of the Physicians' Health Study Research Group, Preliminary report. Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988; 318: 262-264.
4. Steering Committee of the Physicians' Health Study Research Group, Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321:129-135.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group, Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360.
6. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
7. Antiplatelet Trialists' Collaboration, Collaborative overview of randomised trials of antiplatelet therapy - II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308:159-168.
8. Antiplatelet Trialists' Collaboration, Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
9. Picot D, Loll PJ, Garavito RM. X-ray crystallographic study of the structure of prostaglandin H synthase. Adv Exp Med Biol 1997; 400A:107-111.
10. Loll PJ, Picot D, Ekabo O, Garavito RM. Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry (Mosc) 1996; 35:7330-7340.
11. Savi P, Heilmann E, Nurden P et al. Clopidogrel: an antithrombotic drug acting on the ADP dependent pathway of human platelets. Clin Appl Thromb Hemost 1996; 2:35-42. Reference Type: Generic.
12. Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2-methylthio ADP to rat platelets - effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269:772-777.
13. Bellavance A. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The ticlopidine aspirin stroke study. Stroke 1993; 24:1452-1457.
14. CAPRIE Steering Committee, A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
15. Yusuf S et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
16. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53:313-325.
17. Cambria-Kiely JA, Gandhi PJ. Possible mechanisms of aspirin resistance. J Thromb Thrombolysis 2002; 13:49-56.
18. Macchi L et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2003; 107:45-49.
19. Eikelboom JW et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650-1655.
20. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13:37-40.
21. Helgason CM et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25:2331-2336.
22. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995; 11:221-227.
23. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 1994; 118:801-804.
24. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991; 63:587-593.
25. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
26. Mueller MR et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-1007.
27. Leng GC, Fowkes FGR. The epidemiology of peripheral arterial disease. Vasc Med Rev 1993; 4:5-18.
28. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-2436.
29. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102:840-845.
30. Vane JR. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38:97-120.
31. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002; 105:1620-1622.
32. Valles J et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 1991; 78:154-162.
33. Santos MT et al. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation 1997; 95:63-68.
34. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. P1(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666-2672.
35. Sperr W, Huber K, Roden M. Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young Central Europeans. Thromb Res 1998; 90:117-123.
36. Cipollone F et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000; 102:1007-1013.
37. Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000; 31:591-595.
38. Zimmermann N et al. Aspirin resistance after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 121:982-984.
39. Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J 1998; 32:233-237.
40. Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol 2001; 134:353-358.
41. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003; 108:37-42.
42. Mammen EF et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195-202.
43. Vane J. Control of the circulation by endothelial mediators. Inaugural G.B. West Memorial Lecture. Int Arch Allergy Immunol 1993; 101:333-345.
44. Mammen EF et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195-202.
45. Homoncik M et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000; 83:316-321.
46. Hézard N et al. PFA-100™ and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb Res 2003; 108:43-47.
47. Malinin AI, Atar D, Callahan KP, McKenzie ME, Serebruany VL. Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. Eur J Pharmacol 2003; 462:139-143.
48. Bowbrick VA, Mikhailidis DP, Stansby G. Value of thromboelastography in the assessment of platelet function. Clin Appl Thromb Hemost 2003; 9:137-142.
49. Patrono C et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119:39S-63S.
50. UK-TIA Study Group, United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br Med J (Clin Res Ed) 1988; 296:316-320.
51. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044-1054.
52. Feng D et al. Effect of aspirin dosage and enteric coating on platelet reactivity. Am J Cardiol 1997; 80:189-193.
53. Hart RG et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy 2003; 23:579-584.
54. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994; 89:1951-1957.
55. Li N, Wallen NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999; 100:1374-1379.
56. Hurlen M, Seljeflot I, Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res 2000; 99: 487-494.
57. Christiaens L et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 2002;.
58. Gum PA, Kottke-Marchant K, Welsh P, White J, Topol EJ. A prospective blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41:961-965.
59. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250:63-66.
60. Buchanan MR et al. Results of the BRAT study - a pilot study investigating the possible significance of ASA non-responsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000; 16:1385-1390.